Blog
We intend to publish a series of articles describing the evolution of biopharma IP analysis using frontier AI technologies.
-
9 min readDiligence is VigilanceThe final article in a series about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia -
8 min readFirst-in-Class is the Only ClassThe fourth in a five-part series of articles about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia -
7 min readChoosing the RidgeThe third in a five-part series of articles about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia -
6 min readReading the Spec, Not the Press ReleaseThe second in a five-part series of articles about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia -
6 min readThe Dog That Stopped BarkingAn introduction to an article series about how biopharma BD&L should use the patent record in a post-FOIA world.#bd&l#post-foia